Ali Rowhani-Rahbar, PhD, MD, MPH

Assistant Professor, Epidemiology

Contact Information
University of Washington
Office: F-262B
Box 357236
Department of Epidemiology
Health Sciences
Seattle, WA 98195
Tel: 206-221-1602
Fax: 206-543-8525
rowhani@uw.edu

Research Interests
Dr. Rowhani-Rahbar's research is primarily in the area of epidemiology and control of vaccine-preventable diseases. Specifically, he focuses on the examination of vaccine efficacy, effectiveness, immunogenicity, and safety. In addition, he studies the application of epidemiologic methods in public health and clinical research.

Teaching Interests
Dr. Rowhani-Rahbar co-teaches EPI 512 "Epidemiologic Methods I" in the Autumn Quarter and EPI 513 "Epidemiologic Methods II" in the Winter Quarter.

Education
PhD, Epidemiology, University of Washington, School of Public Health 2009
MPH, Epidemiology, Yale University, School of Public Health 2005
MD, Mashhad University of Medical Sciences (Iran), School of Medicine 2002

Selected Publications
Rowhani-Rahbar A, Klein NP, Lewis N, Fireman B, Ray P, Rasgon B, Black S, Klein JO, Baxter R. Immunization and Bell's palsy in children: A case-centered analysis. Am J Epidemiol 2012;175:878-85.

Pahud BA, Rowhani-Rahbar A, Fireman B, Dekker CL, Sheikh L, Salibay C, Gavali S, Glaser C. Lack of association between immunization and pediatric encephalitis in California. Vaccine 2012;30:247-53.

Rowhani-Rahbar A, Alvarez FB, Bryan JT, Hawes SE, Hughes JP, Weiss NS, Koutsky LA. Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. J Clin Virol 2012;53:239-43.

Troy SB, Rowhani-Rahbar A, Dyner L, Musingwini G, Shetty A, Woelk G, Stranix-Chibanda L, Nathoo K, Maldonado YA. Hematologic and immunologic parameters in Zimbabwean infants: A case for using local reference intervals to monitor toxicities in clinical trials. J Trop Pediatr 2012;58:59-62.

Rowhani-Rahbar A, Mao C, Alvarez FB, Bryan JT, Hawes SE, Hughes JP, Weiss NS, Koutsky LA. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009;27:5612-9.

Last Reviewed on 6/15/2012